Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 8Uterine Cervical Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Rectal Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Neoplasms 1Muscle-invasive Bladder Cancer 1Mouth Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Body Weight Changes 1

Interventions

Gemcitabine 12Mitomycin 6Docetaxel 4Radiotherapy 3BCG Vaccine 3tislelizumab 2erdafitinib 2dodecyl maltoside 2disitamab vedotin 2toripalimab 1pemigatinib 1pembrolizumab 1monalizumab 1linrodostat 1enzalutamide 1durvalumab 1bicalutamide 1avelumab 1Watchful Waiting 1Sugars 1Postoperative Period 1Pentosan Sulfuric Polyester 1Nonsteroidal Anti-Androgens 1Nivolumab 1Metformin 1Imiquimod 1Hyaluronic Acid 1High-Intensity Interval Training 1Gels 1Epirubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Non-Muscle Invasive Bladder Neoplasms × Watchful Waiting × Clear all
NCT07625527 2026-06-04

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

Tianjin Medical University Second Hospital

Phase 2 Not yet recruiting
120 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡